Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple MyelomaBusiness Wire • 01/30/23
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead SciencesInvestors Business Daily • 12/09/22
Arcellx flies on $325M deal with Gilead's Kite for multiple myeloma treatmentProactive Investors • 12/09/22
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple MyelomaBusiness Wire • 12/09/22
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline ProgressPRNewsWire • 12/09/22
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple MyelomaPRNewsWire • 12/09/22
Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and ExpositionPRNewsWire • 11/03/22
Wall Street Analysts Think Arcellx, Inc. (ACLX) Could Surge 62%: Read This Before Placing a BetZacks Investment Research • 09/08/22
Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare ConferencePRNewsWire • 09/07/22
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial ResultsPRNewsWire • 08/15/22
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional SharesPRNewsWire • 06/21/22
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual MeetingPRNewsWire • 06/03/22
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meetingMarket Watch • 05/27/22